AN2 Therapeutics Reports Positive Data for Oral Chagas Disease Treatment

AN2 Therapeutics announced positive results for AN2-502998, achieving 100% parasite elimination in nonhuman primates with a favorable safety profile in Phase 1 testing. The company plans to advance the oral CPSF3 inhibitor to Phase 2 studies for chronic Chagas disease, addressing a significant unmet medical need affecting over 300,000 people in the U.S.